16 analysts have shared their evaluations of Gilead Sciences (NASDAQ:GILD) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year ...

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human ...

Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Just Released: Zacks Top 10 Stocks for 2025 Hurry – you can ...

(RTTNews) - Gilead Sciences Inc. (GILD ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at ...